Pacific Edge redoubles US efforts, flags 2022 SE Asian push
Revenue and test numbers up in first half despite Covid headwinds.
Dual-listed cancer diagnostics firm Pacific Edge Health has almost doubled its US sales team – from 16 reps in April to 30 by the end of this month – following a $103.5 million capital raise to accelerate its growth in the lucrative US market.
The goal is 50 reps within the next 18 months to
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
Individual
Group membership
NBR Marketplace
Yearly Premium Online Subscription
NZ$499.00 / yearly
Subscribe Now
Monthly Premium Online Subscription
NZ$44.95 / monthly
Subscribe Now
Smartphone Only Subscription
NZ$24.95 / monthly
Subscribe Now
Premium Group Membership 10 Users
NZ$350+GST / monthly
$35 per user - Pay by monthly
credit card debit
Subscribe Now
Premium Group Membership 20 Users
NZ$600+GST / monthly
$30 per user - Pay by monthly
credit card debit
Subscribe Now
Premium Group Membership 50 Users
NZ$1250+GST / monthly
$25 per user - Pay by monthly
credit card debit
Subscribe Now
Premium Group Membership 100 Users
NZ$1875+GST / monthly
$18.75 per user - Pay by monthly
credit card debit
Subscribe Now
Yearly Premium Online Subscription + NBR Marketplace
NZ$499.00 / yearly
Subscribe Now
Already have an account? Login
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
